The endangered whales must contend with up to 1,000 boats moving daily through an important feeding area in the eastern South Pacific, according to research published in the scientific journal Nature.@WeDontHaveTime
#ForNature @JohnKerry

Super excited to share my very first lead-author paper in @ScienceAdvances

Supported by @HIRN_CC @NIDDKgov @UFBME @UFWertheim @ufdiabetes @UMCoEDean
Lead by @Cherie_Stabler & @ashu83

link: https://t.co/FbqVWQ0n5p

This is a thread 👇

Highlights:
⚪️A Lab-on-a-Chip platform for organoids w/ wide capabilities: long-term culture | controlled & dynamic perifusion | in situ spatio-temporal imaging | serial cell assessment | ease of sample retrieval

⚪️Continuous fluidic flow increased local oxygen supply to islets in hydrogels & reduced cellular hypoxia
⚪️Flow increased cellular viability & reduced apoptosis & cell death

⚪️Human islets in hydrogels were highly functional during the 10 day in situ culture in our chips, while islet function was rapidly lost under static conditions
⚪️Glucolipotoxicity study showed a treatment window as small as 2.5 hours can elevate cell death

What are organoids? – A miniaturized version of an organ that imitate an aspect of human interface. They are commonly developed from stem cells in a lab. Human body also produces organoids naturally particularly within the pancreas.

With @franklowery our new study on attributes of T cells that contribute to successful cell therapy in cancer patients in @ScienceMagazine today w/ colleagues @slgoff_SB, @NCI_CCR_SB @theNCI a TL;DR thread on key findings with caveats :) 1/10

has a long history of using tumor infiltrating T cells (TILs) to treat cancers since well.. before I was even born. We analyzed our most successful melanoma ACT trial for cell surface phenotypes in TIL infusion products of patients (aPD1/immunotherapy naive) /2

Surprisingly we found a CD39- TIL subset (CD39-CD69-, DN) associated with ACT-response. TBH we were expecting the opposite (CD39+). We only included CD39 bcz multiple groups (e.g. Simoni et al, 2018) had reported CD39+ as enriching for anti-tumor/neoantigen reactive T cells. /3

CD39- DN TILs RNA/epigenetics resemble stem-like memory progenitors, and in vitro were able to self-renew, and give rise to other CD39+ subsets. OTOH the most dominant subset of patient infusion products were CD39+ CD69+ (DP) and these guys were terminally differentiated.. /4

So, to clarify we specifically analyzed tumor-specific mutation-reactive Tcells. Turns out, ACT-responders had pool of neoantigen-reactive TILs in the CD39- phenotype, while non-responders did not (despite other irrelevant CD39- Tcells) -> not all CD39- T cells are bystanders /5

Fellow academics, when are we going to start fixing our urgent structural problems that strain family bonds and present ongoing barriers to diversifying our educational and scientific leadership? You wonder, what the heck is this guy talking about?
1/n

We’re all very familiar what I am talking about, actually: the impossibility for most academics in the life sciences to do their jobs in a reaonable amount of time, due to more and more demands on writing grants, and to a lesser degree, papers.
2/n

As of yesterday I hadn’t intended to write about this subject, but was wondering as I finished a Saturday of straight work, what happened to all my time? Why has WFH not reduced my pile of tasks to do? Instead why is my to-do list growing bigger and bigger?
3/n

I decided to figure out how much time our jobs actually require. I estimated per year (m=month, w=week, d=day, h=hour):
Teaching: 20h/w x 20w = 400h
Meetings of all sorts: 10h/w x 48w= 480h
Replying to email: 2h/d x 365d = 730h
Attending and giving talks: 2h/w x 50w = 100h
4/n

Papers: If each person needs 2 papers during a 5y stint, and you run a 7.5-person lab, then you need 7.5 papers per 2.5y = 3 papers/y. Throw in a review and it’s 4 papers. If you need 15d at 8h/d per paper, that’s 480h writing papers.
5/n